Antibody · CD20

5개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved5 programs
AntibodyCurated CoreFDARocheApproved

glofitamab (Columvi, RO7082859, glofitamab-gxbm)

Relapsed or refractory diffuse large B-cell lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 90Status Approved
AntibodyCurated CoreFDAGenmabApproved

epcoritamab (Epkinly, GEN3013, Tepkinly, epcoritamab-bysp)

Relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma · CD20 × CD3

#CD20CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 57Status Approved
AntibodyLimited DatastaleRochePhase 3

Ocrelizumab, Rituximab, Ofatumumab (Anti-CD20 therapies, Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab))

Relapsing-Remitting Multiple Sclerosis (RRMS); Anti-CD20 Therapy · CD20

#CD20#Antibody#Phase3#monoclonal-antibody#Relapsing-RemittingMultipleScler+3
Trials 40Status Recruiting
AntibodyStandard DatabasestaleKyverna TherapeuticsPhase 2

Anti-CD20 mAB (Anti-CD20 mAB)

Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive · CD20

#CD20#Antibody#Phase2#monoclonal-antibody#MultipleSclerosis+3
Trials 31Status Recruiting
AntibodyLimited DatastaleRochePhase 2

rituximab (Anti-CD20, Anti-CD20 (rituximab))

Presymptomatic Diabetes Type 1 (Stage 1); Diabetes Mellitus, Type I · CD20

#CD20#Antibody#Phase2#monoclonal-antibody#PresymptomaticDiabetesType1Stage+3
Trials 2Status Active